Skip to main content

FDA Approves Tbo-Filgrastim for Neutropenia



August 29, 2012 — The US Food and Drug Administration (FDA) has approved tbo-filgrastim (Sicor Biotech/Teva Pharmaceuticals) for the treatment of severe neutropenia associated with use of chemotherapy in nonmyeloid malignancies.
Filgrastim is a granulocyte colony-stimulating factor (G-CSF) analog used to stimulate the proliferation and differentiation of granulocytes. Two forms of filgrastim are already available in the US — one injected daily (Neupogen, Amgen) and a pegylated form injected once per chemotherapy cycle (Neulasta, Amgen); another version of filgrastim (Tevagrastim, Teva) has been marketed outside of the US. Teva notes that Tevagrastim and Neupogen are biosimilar, and that the Neupogen patent will expire in the US next year. The company also notes that that tbo-filgrastim is a short-acting recombinant form of G-CSF, and that it is the first new G-CSF to be approved in the US in more than 10 years. Teva reports that it will start marketing tbo-filgrastim possibly as early as November 2013, in accordance with the settlement it reached with Amgen.
Approval of tbo-filgrastim was based on the findings of a clinical study of 348 adult patients with advanced breast cancer receiving treatment with the anticancer drugs doxorubicin and docetaxel. Patients were randomly assigned to receive tbo-filgrastim, a placebo, or a filgrastim product not available in the US.
Patients receiving tbo-filgrastim recovered from severe neutropenia in 1.1 days compared with 3.8 days in those receiving the placebo.
Adverse events associated with tbo-filgrastim were evaluated in 3 clinical studies including 680 adults with breast cancer, lung cancer, or non-Hodgkin's lymphoma receiving high-dose myeloablative chemotherapy. The most common side effect observed in those receiving tbo-filgrastim was bone pain.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...
Post a Comment
Read more

FDA Approvals: Pazopanib for Advanced Soft Tissue Sarcoma

CLINICAL CONTEXT Pazopanib was first approved by the US Food and Drug Administration (FDA) in 2009 when it became the sixth drug approved to treat advanced renal cell carcinoma. It is a small molecule with a mechanism of action as a tyrosine kinase inhibitor, specifically targeting receptors involved in angiogenesis and tumor cell proliferation. These include vascular endothelial growth-factor receptors 1, 2, and 3; platelet-derived growth-factor receptors α and β; fibroblast growth-factor receptors 1 and 3; stem cell factor receptors; interleukin-2-inducible T-cell kinase; leukocyte-specific protein tyrosine kinase; and transmembrane glycoprotein-receptor tyrosine kinase. STUDY SYNOPSIS AND PERSPECTIVE The FDA has approved pazopanib ( Votrient ) for the treatment of advanced soft tissue sarcoma in patients who have received previous chemotherapy. Pazopanib is already marketed for the treatment of advanced renal cell carcinoma; when it was approved in 2009, it became the six...
Post a Comment
Read more